The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

We describe here a newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20–27% amino acid identity with other B7 family members. B7-H3 mRNA is not ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...

Post the identification of immune checkpoints, research studies were focused on identifying more immune checkpoints and the B7-H3 was one of those discovered in the early 2000s. The protein has ...

Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors In this Phase 1/2 ...

B7-H3, also known as CD276, is an immunoregulatory protein that is overexpressed in tumour tissue, notably in lung, breast, ovarian, gastric, and brain cancer, as well as squamous cell carcinoma ...

It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented ...

The setback means two of MacroGenics’ three attacks on the protein B7-H3 have hit setbacks, but the biotech is forging ahead with the third candidate. Having stopped development of a B7-H3xCD3 ...

Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the ...

HS-20093 is a B7-H3 targeted ADC that uses a topoisomerase inhibitor (TOPOi) payload and has shown promise in treating lung cancer. The drug may also hold potential in treating sarcoma, head and neck ...